Suggestions
Gerry (Gerald) Klein, MD
Principal at MedSurgPI, LLC & Medical Consulting for Fractional Chief Medical Officer and Medical Monitoring
Gerry (Gerald) Klein, MD is an experienced medical professional with a diverse background in pharmacology, toxicology, and clinical research. He currently serves as an Adjunct Professor of Pharmacology and Toxicology at the Brody School of Medicine, East Carolina University.13
Dr. Klein's career highlights include:
-
Principal at MedSurgPI, LLC, providing novel medical affairs services for pharmaceutical, biotechnology, and medical device companies.1
-
Former President and CEO of Entera Health, where he co-founded a biotherapeutic company and developed strategic plans.1
-
Chief Medical Officer (CMO) and VP of Medical and Clinical Affairs at various companies, including Talecris Biotherapeutics (Grifols) and Merck KGaA (Dey).1
-
Founder and Senior Partner of Allergy Immunology Medical Group, where he maintained a private practice and served as a Clinical Professor of Medicine and Pediatrics at the University of California, Irvine.1
-
Current CMO of Claradele, an early-stage oncology company.2
Dr. Klein's educational background includes:
- MD from Vrije Universiteit Brussel (1969-1975)
- B.S. in Psychology from the University of Florida (1965-1969)1
He holds certifications in Pediatrics from the American Board of Pediatrics and in Allergy, Asthma, and Clinical Immunology from the American Board of Allergy and Immunology.1
Dr. Klein is recognized for his expertise in Medical Affairs and Clinical Development, having published numerous scientific papers and served on editorial boards of several publications.2
Highlights
MedSurgPI wishes to thank everyone who participated in our two recent polls. A brief description of the poll results are shown on the attached.
Roger Morgan, MD FACS
Congratulations to Alethea Wieland, President and Founder of Clinical Research Strategies and a member of the MedSurgPI team for co-authoring the attached publication: Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe, featured in Therapeutic Innovation & Regulatory Science. #osteoporosis #tymlos #fda #ema #regulatorydecision #realworlddata #realworldevidence #abaloparatide #eladynos #tymlos #medicalresearch
